Cargos activos de Steven J. Evans
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Oncolyze, Inc.
 Oncolyze, Inc. BiotechnologyHealth Technology Oncolyze, Inc. is a private company developing a novel technology for cancer treatment. The company is based in New York, NY and was founded by Steven J. Evans and John H. Abeles. The company's lead drug candidate targets the cancer cell membrane and selectively kills cancer cells and cancer stem cells while sparing normal cells, potentially providing a highly effective treatment with little to no side effects. The initial therapeutic target is acute myeloid leukemia (AML), a cancer with a low five-year survival rate. Oncolyze's drug has been shown to destroy leukemic cancer stem cells, disrupting current medical treatment. Steven J. Evans has been the CEO since incorporation. | Director/Miembro de la Junta | - | - |
| Director Ejecutivo | - | - | |
| Fundador | - | - |
Historial de carrera de Steven J. Evans
Estadísticas
Internacional
| Estados Unidos | 2 |
Operativa
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
| Founder | 1 |
Sectorial
| Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
Oncolyze, Inc.
Oncolyze, Inc. BiotechnologyHealth Technology Oncolyze, Inc. is a private company developing a novel technology for cancer treatment. The company is based in New York, NY and was founded by Steven J. Evans and John H. Abeles. The company's lead drug candidate targets the cancer cell membrane and selectively kills cancer cells and cancer stem cells while sparing normal cells, potentially providing a highly effective treatment with little to no side effects. The initial therapeutic target is acute myeloid leukemia (AML), a cancer with a low five-year survival rate. Oncolyze's drug has been shown to destroy leukemic cancer stem cells, disrupting current medical treatment. Steven J. Evans has been the CEO since incorporation. | Health Technology |
- Bolsa de valores
- Insiders
- Steven J. Evans
- Experiencia
